Imfinzi improved event-free survival and overall survival for bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Subscribe To Our Newsletter & Stay Updated